世界の去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬市場 2021：企業別、地域別、種類・用途別

• 英文タイトル：Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market 2021 by Company, Regions, Type and Application, Forecast to 2026

• レポートコード：GIR-2104Z02892 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、108ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥487,200 (USD3,480)	▷ お問い合わせ
Multi User	￥730,800 (USD5,220)	▷ お問い合わせ
Corporate User	￥974,400 (USD6,960)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料では、去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の種類別市場規模（経口療法、注射療法）、用途別市場規模（病院・診療所、自宅設定、外来手術センター（ASC））、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Astellas Inc.、Johnson & Johnson、Sanofi S.A、Dendreon Corporation、Bayer AG ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：経口療法、注射療法 ・用途別分析2016年-2026年：病院・診療所、自宅設定、外来手術センター（ASC） ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・去勢抵抗性前立腺がん（CRPC）/ HRPCA治療薬の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論

The Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest research, the global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics size is estimated to be USD 9300.5 million in 2025 from USD 7669.7 million in 2019, with a change XX% between 2019 and 2020. The global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market size is expected to grow at a CAGR of 4.9% for the next five years.

Market segmentation
Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers
Oral Therapy
Injectable Therapy

Market segment by Application, can be divided into
Hospitals & Clinics
Home Settings
Ambulatory Surgical Centers (ASCs)

Market segment by players, this report covers
Astellas Inc.
Johnson & Johnson
Sanofi S.A
Dendreon Corporation
Bayer AG

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

レポート目次

---

1 Market Overview
1.1 Product Overview and Scope of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics
1.2 Classification of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Type
1.2.1 Overview: Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type in 2020
1.2.3 Oral Therapy
1.2.4 Injectable Therapy
1.3 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market by Application
1.3.1 Overview: Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospitals & Clinics
1.3.3 Home Settings
1.3.4 Ambulatory Surgical Centers (ASCs)
1.4 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size & Forecast
1.5 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast by Region
1.5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers
1.6.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints
1.6.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Trends Analysis
2 Company Profiles
2.1 Astellas Inc.
2.1.1 Astellas Inc. Details
2.1.2 Astellas Inc. Major Business
2.1.3 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
2.1.4 Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Astellas Inc. Recent Developments and Future Plans
2.2 Johnson & Johnson
2.2.1 Johnson & Johnson Details
2.2.2 Johnson & Johnson Major Business
2.2.3 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
2.2.4 Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Johnson & Johnson Recent Developments and Future Plans
2.3 Sanofi S.A
2.3.1 Sanofi S.A Details
2.3.2 Sanofi S.A Major Business
2.3.3 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
2.3.4 Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Sanofi S.A Recent Developments and Future Plans
2.4 Dendreon Corporation
2.4.1 Dendreon Corporation Details
2.4.2 Dendreon Corporation Major Business
2.4.3 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
2.4.4 Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Dendreon Corporation Recent Developments and Future Plans
2.5 Bayer AG
2.5.1 Bayer AG Details
2.5.2 Bayer AG Major Business
2.5.3 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
2.5.4 Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Bayer AG Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Market Share
3.2.2 Top 10 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2026)
6.2 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2026)
6.3 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
6.3.1 North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2026)
7.2 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2026)
7.3 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
7.3.1 Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Region
8.3.1 Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Region (2016-2026)
8.3.2 China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2026)
9.2 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2026)
9.3 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
9.3.1 South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size by Country
10.3.1 Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

List of Tables
Table 1. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Astellas Inc. Corporate Information, Head Office, and Major Competitors
Table 7. Astellas Inc. Major Business
Table 8. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 9. Astellas Inc. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 11. Johnson & Johnson Major Business
Table 12. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 13. Johnson & Johnson Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Sanofi S.A Corporate Information, Head Office, and Major Competitors
Table 15. Sanofi S.A Major Business
Table 16. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 17. Sanofi S.A Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Dendreon Corporation Corporate Information, Head Office, and Major Competitors
Table 19. Dendreon Corporation Major Business
Table 20. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 21. Dendreon Corporation Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Bayer AG Corporate Information, Head Office, and Major Competitors
Table 23. Bayer AG Major Business
Table 24. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Product and Solutions
Table 25. Bayer AG Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 27. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Players (2019-2021)
Table 28. Breakdown of Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 29. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Players Head Office, Products and Services Provided
Table 30. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Mergers & Acquisitions in the Past Five Years
Table 31. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics New Entrants and Expansion Plans
Table 32. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 33. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Type (2016-2021)
Table 34. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Forecast by Type (2021-2026)
Table 35. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2021)
Table 36. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Forecast by Application (2021-2026)
Table 37. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 38. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 39. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 40. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 41. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 42. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 43. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 44. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 45. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 46. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 47. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 48. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 49. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 50. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 51. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 52. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 53. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 54. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 55. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 56. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 57. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 58. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 59. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 60. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 61. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 62. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 63. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 64. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 65. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 66. Middle East & Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Picture
Figure 2. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Type in 2020
Figure 3. Oral Therapy
Figure 4. Injectable Therapy
Figure 5. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Application in 2020
Figure 6. Hospitals & Clinics Picture
Figure 7. Home Settings Picture
Figure 8. Ambulatory Surgical Centers (ASCs) Picture
Figure 9. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 10. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 11. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region (2016-2026)
Figure 12. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region in 2020
Figure 13. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Drivers
Figure 18. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Restraints
Figure 19. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Trends
Figure 20. Astellas Inc. Recent Developments and Future Plans
Figure 21. Johnson & Johnson Recent Developments and Future Plans
Figure 22. Sanofi S.A Recent Developments and Future Plans
Figure 23. Dendreon Corporation Recent Developments and Future Plans
Figure 24. Bayer AG Recent Developments and Future Plans
Figure 26. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Players in 2020
Figure 27. Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 28. Global Top 3 Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share in 2020
Figure 29. Global Top 10 Players Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share in 2020
Figure 30. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 31. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Type in 2020
Figure 32. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share Forecast by Type (2021-2026)
Figure 33. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Share by Application in 2020
Figure 34. Global Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Market Share Forecast by Application (2021-2026)
Figure 35. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2016-2026)
Figure 36. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2016-2026)
Figure 37. North America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2016-2026)
Figure 38. United States Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 39. Canada Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 40. Mexico Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 41. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2016-2026)
Figure 42. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2016-2026)
Figure 43. Europe Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2016-2026)
Figure 44. Germany Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 45. France Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 46. United Kingdom Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 47. Russia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Italy Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2016-2026)
Figure 50. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2016-2026)
Figure 51. Asia-Pacific Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Region (2016-2026)
Figure 52. China Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 53. Japan Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. South Korea Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. India Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Southeast Asia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Australia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2016-2026)
Figure 59. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2016-2026)
Figure 60. South America Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2016-2026)
Figure 61. Brazil Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Argentina Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Type (2016-2026)
Figure 64. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Sales Market Share by Application (2016-2026)
Figure 65. Middle East and Africa Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue Market Share by Country (2016-2026)
Figure 66. Turkey Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. Saudi Arabia Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 68. UAE Castration-Resistant Prostate Cancer (CRPC)/HRPCA Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 69. Methodology
Figure 70. Research Process and Data Source

---